Response-Guided Therapy: Optimizing Treatment now and in the Future

Fried M.W. , Shiffman M.L. , Reddy K.R. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.

Hadziyannis S.J. , Sette H. Jr. , Morgan T.R. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.

Zeuzem S. , Pawlotsky J.M. , Lukasiewicz E. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43: 250–257.

Marcellin P. , Boyer N. , Gervais A. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875–881.

Foster G. , Mathurin P. Hepatitis C virus therapy to date. Antivir Ther 2008; 13 Suppl 1: 3–8.

Lee S.S. , Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008; 13 Suppl 1: 9–16.

Berg T. , Carosi G. Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. Antivir Ther 2008; 13 Suppl 1: 17–22.

Dusheiko G. , Nelson D. , Reddy K.R. Ribavirin considerations in treatment optimization. Antivir Ther 2008; 13 Suppl 1: 23–30.

Jensen D.M. , Ascione A. Future directions in therapy for chronic hepatitis C. Antivir Ther 2008; 13 Suppl 1: 31–36.